This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2009 Apr 9;52(7):1785-94.

doi: 10.1021/jm8013019.

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2

William N Washburn¹

Affiliations

PMID: 19243175
DOI: 10.1021/jm8013019

Review

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2

William N Washburn. J Med Chem. 2009.

. 2009 Apr 9;52(7):1785-94.

doi: 10.1021/jm8013019.

Author

William N Washburn¹

Affiliation

¹ Metabolic Diseases Chemistry, Research and Development, Bristol-Myers Squibb Co, Princeton, New Jersey 08543, USA.

PMID: 19243175
DOI: 10.1021/jm8013019

No abstract available

PubMed Disclaimer

Similar articles

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
Washburn WN. Washburn WN. Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Expert Opin Ther Pat. 2009. PMID: 19852718 Review.
C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B, Feng Y, Cheng H, Song Y, Lv B, Wu Y, Wang C, Li S, Xu M, Du J, Peng K, Dong J, Zhang W, Zhang T, Zhu L, Ding H, Sheng Z, Welihinda A, Roberge JY, Seed B, Chen Y. Xu B, et al. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4465-70. doi: 10.1016/j.bmcl.2011.06.032. Epub 2011 Jun 16. Bioorg Med Chem Lett. 2011. PMID: 21737266
Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ. Bailey CJ. Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4. Trends Pharmacol Sci. 2011. PMID: 21211857 Review.
Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B, Feng Y, Dong J, Xu M, Xu B, Zhang W, Sheng Z, Welihinda A, Seed B, Chen Y. Lv B, et al. ChemMedChem. 2010 Jun 7;5(6):827-31. doi: 10.1002/cmdc.201000051. ChemMedChem. 2010. PMID: 20414917 No abstract available.
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E, Ogasawara H. Kurosaki E, et al. Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Pharmacol Ther. 2013. PMID: 23563279 Review.

See all similar articles

Cited by

SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK, Zhang LN, Feng Y, Qu H, Qin L, Zhang LS, Leng Y. Yan PK, et al. Acta Pharmacol Sin. 2014 May;35(5):613-24. doi: 10.1038/aps.2013.196. Acta Pharmacol Sin. 2014. PMID: 24786232 Free PMC article.
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.
Hardman TC, Dubrey SW. Hardman TC, et al. Diabetes Ther. 2011 Sep;2(3):133-45. doi: 10.1007/s13300-011-0004-1. Epub 2011 Jun 28. Diabetes Ther. 2011. PMID: 22127823 Free PMC article.
Structural selectivity of human SGLT inhibitors.
Hummel CS, Lu C, Liu J, Ghezzi C, Hirayama BA, Loo DD, Kepe V, Barrio JR, Wright EM. Hummel CS, et al. Am J Physiol Cell Physiol. 2012 Jan 15;302(2):C373-82. doi: 10.1152/ajpcell.00328.2011. Epub 2011 Sep 21. Am J Physiol Cell Physiol. 2012. PMID: 21940664 Free PMC article.
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Rosenstock J, Vico M, Wei L, Salsali A, List JF. Rosenstock J, et al. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23. Diabetes Care. 2012. PMID: 22446170 Free PMC article. Clinical Trial.
SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis.
Han JX, Luo LL, Wang YC, Miyagishi M, Kasim V, Wu SR. Han JX, et al. Acta Pharmacol Sin. 2023 Jun;44(6):1161-1174. doi: 10.1038/s41401-022-01031-0. Epub 2022 Dec 12. Acta Pharmacol Sin. 2023. PMID: 36509902 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- American Chemical Society
Other Literature Sources
- The Lens - Patent Citations Database
Chemical Information
- BindingDB
Medical
- MedlinePlus Health Information